We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

259 hedge funds and large institutions have $2.93B invested in Pacific Biosciences in 2023 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 86 increasing their positions, 60 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more call options, than puts

Call options by funds: $59.3M | Put options by funds: $18.5M

86% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 29

60% more capital invested

Capital invested by funds: $1.83B → $2.93B (+$1.1B)

43% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 60

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

10% more funds holding

Funds holding: 236 → 259 (+23)

3.1% more ownership

Funds ownership: 99.45% → 102.55% (+3.1%)

Holders
259
Holders Change
+23
Holders Change %
+9.75%
% of All Funds
4.13%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
54
Increased
86
Reduced
60
Closed
29
Calls
$59.3M
Puts
$18.5M
Net Calls
+$40.8M
Net Calls Change
+$30.7M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$41.9M
2
APM
Avidity Partners Management
Texas
+$37.9M
3
DTC
Deep Track Capital
Connecticut
+$34.8M
4
FCM
Farallon Capital Management
California
+$23.4M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$22.9M

Top Sellers

1
JSP
Jackson Square Partners
California
-$28.9M
2
Capital International Investors
Capital International Investors
California
-$18.7M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$7.76M
4
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$6.46M
5
Millennium Management
Millennium Management
New York
-$5.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
276
Shell Asset Management
Netherlands
– -$55K -6,775 Closed
Rockefeller Capital Management
277
Rockefeller Capital Management
New York
– -$8K -1,018 Closed
Parallax Volatility Advisers
278
Parallax Volatility Advisers
California
– -$8.12K -993 Closed
CS
279
Comerica Securities
Michigan
– -$6.09K -744 Closed
Fifth Third Bancorp
280
Fifth Third Bancorp
Ohio
– -$3.27K -400 Closed
PCM
281
Penserra Capital Management
California
– -$2K -310 Closed
RBC
282
Romano Brothers & Co
Illinois
– -$1.86K -227 Closed
BTI
283
Blue Trust Inc
Georgia
– -$1K -173 Closed
CWP
284
Concord Wealth Partners
Virginia
– -$188 -23 Closed
SFG
285
Steward Financial Group
Texas
– +$249 +25 New
8 9 10 11
12

PACB Hedge Fund Activity: Q1 2023 in Review

259 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2023, worth a combined $2.93B — up 60% from $1.83B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new PACB positions and 29 closed out — a net gain of 25 holders — while 86 added to existing stakes and 60 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $41.9M. The largest seller was Jackson Square Partners, cutting an estimated $28.9M.

  • 259 institutional investors held Pacific Biosciences (PACB) as of Q1 2023, up from 236 in Q4 2022.
  • Funds reported $2.93B of Pacific Biosciences stock for Q1 2023, up 60% quarter-over-quarter.
  • 54 funds opened new Pacific Biosciences positions in Q1 2023 and 29 closed out, a net change of +25 holders.
  • The largest Pacific Biosciences buyer in Q1 2023 was Fidelity Investments, an estimated $41.9M added.
  • The largest Pacific Biosciences seller in Q1 2023 was Jackson Square Partners, an estimated $28.9M sold.

Based on aggregated 13F filings for Q1 2023.